H.C. Wainwright analyst Ed Arce raised his price target on Dicerna (DRNA) shares to $24 from $20 after the company announced collaborations with Eli Lilly (LLY) and Alexion Pharmaceuticals (ALXN). Arce views these partnerships as further strong validation of Dicerna’s GalXC RNAi platform and keeps a Buy rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.